JP2010519915A - 二本鎖のロックされた核酸組成物 - Google Patents

二本鎖のロックされた核酸組成物 Download PDF

Info

Publication number
JP2010519915A
JP2010519915A JP2009552038A JP2009552038A JP2010519915A JP 2010519915 A JP2010519915 A JP 2010519915A JP 2009552038 A JP2009552038 A JP 2009552038A JP 2009552038 A JP2009552038 A JP 2009552038A JP 2010519915 A JP2010519915 A JP 2010519915A
Authority
JP
Japan
Prior art keywords
lna
formula
nucleoside
integer
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2009552038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010519915A5 (OSRAM
Inventor
ピーター エムテイジ
Original Assignee
ヌヴェンタ バイオファーマシューティカルズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヌヴェンタ バイオファーマシューティカルズ コーポレイション filed Critical ヌヴェンタ バイオファーマシューティカルズ コーポレイション
Publication of JP2010519915A publication Critical patent/JP2010519915A/ja
Publication of JP2010519915A5 publication Critical patent/JP2010519915A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009552038A 2007-03-07 2008-03-07 二本鎖のロックされた核酸組成物 Abandoned JP2010519915A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90546107P 2007-03-07 2007-03-07
US95027107P 2007-07-17 2007-07-17
PCT/CA2008/000473 WO2008106803A1 (en) 2007-03-07 2008-03-07 Double-stranded locked nucleic acid compositions

Publications (2)

Publication Number Publication Date
JP2010519915A true JP2010519915A (ja) 2010-06-10
JP2010519915A5 JP2010519915A5 (OSRAM) 2011-10-27

Family

ID=39737757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009552038A Abandoned JP2010519915A (ja) 2007-03-07 2008-03-07 二本鎖のロックされた核酸組成物

Country Status (10)

Country Link
US (1) US20090041809A1 (OSRAM)
EP (1) EP2125853A1 (OSRAM)
JP (1) JP2010519915A (OSRAM)
KR (1) KR20100051041A (OSRAM)
CN (1) CN101687900A (OSRAM)
AU (1) AU2008222523A1 (OSRAM)
BR (1) BRPI0808442A2 (OSRAM)
CA (1) CA2680060A1 (OSRAM)
MX (1) MX2009009530A (OSRAM)
WO (1) WO2008106803A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532976A (ja) * 2010-06-25 2013-08-22 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｏｌｌ様レセプター３の新規アゴニストおよびその使用方法

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228540D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compositions
AU2009255947B2 (en) 2008-06-06 2014-12-18 Aurora Algae, Inc. Vcp-based vectors for algal cell transformation
CA2735724C (en) 2008-06-19 2018-07-24 Variation Biotechnologies Inc. Compositions and methods for treating influenza
JP2012520761A (ja) 2009-03-19 2012-09-10 イー・エム・デイー・ミリポア・コーポレイシヨン ナノ繊維濾過媒体を用いる、流体資料からの微生物の除去
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US8865468B2 (en) 2009-10-19 2014-10-21 Aurora Algae, Inc. Homologous recombination in an algal nuclear genome
US8809046B2 (en) 2011-04-28 2014-08-19 Aurora Algae, Inc. Algal elongases
US9029137B2 (en) 2009-06-08 2015-05-12 Aurora Algae, Inc. ACP promoter
WO2011005769A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
US8709765B2 (en) 2009-07-20 2014-04-29 Aurora Algae, Inc. Manipulation of an alternative respiratory pathway in photo-autotrophs
US9366667B2 (en) * 2009-10-02 2016-06-14 The Trustees Of Columbia University In The City Of New York Piscine reovirus diagnostic compositions
US8846388B2 (en) * 2009-10-16 2014-09-30 Zoetis Llc Infectious clones of torque teno virus
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
SG185659A1 (en) 2010-08-10 2012-12-28 Emd Millipore Corp Method for retrovirus removal
EP2655612B1 (en) * 2010-12-23 2017-07-19 Shell Internationale Research Maatschappij B.V. Gene disruptants producing fatty acyl-coa derivatives
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
US8722359B2 (en) 2011-01-21 2014-05-13 Aurora Algae, Inc. Genes for enhanced lipid metabolism for accumulation of lipids
US11154821B2 (en) 2011-04-01 2021-10-26 Emd Millipore Corporation Nanofiber containing composite membrane structures
CN103974966A (zh) 2011-04-28 2014-08-06 奥罗拉藻类股份有限公司 藻类去饱和酶
WO2013096680A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
WO2013111012A2 (en) 2012-01-27 2013-08-01 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9157101B2 (en) 2012-12-21 2015-10-13 Algenol Biotech LLC Cyanobacterium sp. for production of compounds
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
US9994831B2 (en) 2013-12-12 2018-06-12 The Regents Of The University Of California Methods and compositions for modifying a single stranded target nucleic acid
CN112957789A (zh) 2014-06-26 2021-06-15 Emd密理博公司 具有增强的污垢容纳能力的过滤器结构
EP3206751A4 (en) 2014-10-14 2018-06-13 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
WO2016105483A1 (en) 2014-12-23 2016-06-30 Algenol Biotech LLC Methods for increasing the stability of production of compounds in microbial host cells
DK3283202T3 (da) 2015-04-17 2025-12-01 Emd Millipore Corp Fremgangsmåde til rensning af et biologisk materiale af interesse i en prøve gennem brug af ultrafiltreringsmembraner af nanofibre i tangentiel strømningsfiltreringstilstand
WO2016196655A1 (en) 2015-06-03 2016-12-08 The Regents Of The University Of California Cas9 variants and methods of use thereof
US10138489B2 (en) 2016-10-20 2018-11-27 Algenol Biotech LLC Cyanobacterial strains capable of utilizing phosphite
WO2019016605A1 (en) 2017-07-21 2019-01-24 Merck Millipore Ltd MEMBRANES OF NONWOVEN FIBERS
WO2019066571A2 (ko) 2017-09-28 2019-04-04 연세대학교 산학협력단 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도
CA3097620A1 (en) * 2018-05-04 2019-11-07 Tollys Tlr3 ligands that activate both epithelial and myeloid cells
WO2020041456A1 (en) 2018-08-22 2020-02-27 The Regents Of The University Of California Variant type v crispr/cas effector polypeptides and methods of use thereof
EP3877517A4 (en) 2018-11-09 2022-09-07 Inari Agriculture, Inc. RNA-DRIVEN NUCLEASES AND DNA-BINDING PROTEINS
MX2021010559A (es) 2019-03-07 2021-12-15 Univ California Polipéptidos efectores de crispr-cas y métodos de uso de estos.
EP3994265A4 (en) * 2019-07-02 2023-11-29 NA Vaccine Institute NOVEL RIBONUCLEIC ACID AND PHARMACEUTICAL COMPOSITION BASED THEREOF
CA3186367A1 (en) * 2020-08-14 2022-02-17 Tanya DAIGLE Artificial expression constructs for modulating gene expression in striatal neurons
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692899A (en) * 1969-12-17 1972-09-19 Us Health Education & Welfare Inhibition of transplanted tumor growth by polyinosinic-polycytidylic acid in mice
US4024241A (en) * 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US3952097A (en) * 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4349538A (en) * 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
JP3468773B2 (ja) * 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
JP3756313B2 (ja) * 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CA2203843C (en) * 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6083482A (en) * 1999-05-11 2000-07-04 Icn Pharmaceuticals, Inc. Conformationally locked nucleosides and oligonucleotides
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
CA2474709A1 (en) * 2002-02-04 2003-08-14 Biomira, Inc. Immunostimulatory, covalently lipidated oligonucleotides
AU2003248791A1 (en) * 2002-07-03 2005-11-09 Oncovir, Inc. Method for preparation of poly-iclc and uses thereof
GB0228540D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compositions
WO2005004794A2 (en) * 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7834064B2 (en) * 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
WO2007050990A2 (en) * 2005-10-27 2007-05-03 Rosetta Inpharmatics Llc Nucleic acid amplification using non-random primers
US20070197460A1 (en) * 2005-11-01 2007-08-23 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532976A (ja) * 2010-06-25 2013-08-22 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｏｌｌ様レセプター３の新規アゴニストおよびその使用方法

Also Published As

Publication number Publication date
AU2008222523A1 (en) 2008-09-12
EP2125853A1 (en) 2009-12-02
BRPI0808442A2 (pt) 2014-08-05
CA2680060A1 (en) 2008-09-12
KR20100051041A (ko) 2010-05-14
CN101687900A (zh) 2010-03-31
US20090041809A1 (en) 2009-02-12
WO2008106803A1 (en) 2008-09-12
MX2009009530A (es) 2010-05-19

Similar Documents

Publication Publication Date Title
JP2010519915A (ja) 二本鎖のロックされた核酸組成物
ES2526879T3 (es) Composiciones y procedimientos para formulaciones de oligonucleótidos
ES2380796T3 (es) Oligonucleótidos inmunoestimuladores y sus usos.
CA2570786C (en) Modified cpg-containing oligonucleotide multimers in immune stimulation
US20110038888A1 (en) Adjuvant compositions comprising poly-ic and a cationic polymer
KR101092043B1 (ko) 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
US20060025365A1 (en) Immunostimulatory oligonucleotide multimers
EP3024494A1 (en) Spherical nucleic acid-based constructs as immunoregulatory agents
CN101287742A (zh) 基于变异应答调制Toll样受体的免疫调节寡核苷酸（IRO）化合物
US10066230B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
TW200916106A (en) RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
CN112203663A (zh) Cpg两亲分子及其用途
JP2009538836A (ja) 生物活性の精製ＨｓｐＥ７組成物
EP1657307A1 (en) Oligonucleotides that induce the secretion of GM-CSF
JP5359883B2 (ja) 肝炎の治療剤又は予防剤
JP5415724B2 (ja) 一種のオリゴヌクレオチド及びその応用
WO2022094102A1 (en) Immunostimulatory oligonucleotides for the prevention and treatment of covid-19
CN101378776A (zh) 含有CG二核苷酸修饰的TOll样受体的新合成拮抗剂
CN117568339A (zh) CpG寡核苷酸及其应用
JP2014073126A (ja) 一種のオリゴヌクレオチド及びその応用
CA2487904A1 (en) Immunostimulatory oligonucleotides and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110909

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20120105